Am J Leuk Res | Volume 4, Issue 1 | Case Series | Open Access
Mavinahally T*, Hennig T and Rizzieri D
Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, USA
*Correspondance to: Tanushri Mahesh Mavinahally
Fulltext PDFThe incidence rate of leukemia was 13.8% between 2011 to 2015 and the death rate was 6.5% between 2012 to 2016. The data shows that the death rate was almost half of the incidence and need for newer therapies to treat leukemia. Acute myeloid leukemia is characterized by rapid growth of myeloid lineage cells in the bone marrow and appearance of blasts in peripheral blood. The mainstay of treatment is chemotherapy and sometimes given with targeted drug therapy. Targeted drugs work differently compared to standard chemotherapy and when used individually for treatment has given encouraging results. We report a case series of three patients treated at our center for relapsed AML with IDH inhibitor and BCL-2 inhibitor combination for more than 2 months and attained morphological leukemia free state and cytopenia.
Mahesh MT, Hennig T, Rizzieri D. Case Series of Safety of BCL2 and IDH Inhibition Combination for Myeloid Leukemia. Am J Leuk Res. 2020; 4(1): 1019.